Thermo Fisher Scientific Inc. $TMO Shares Sold by Confluence Investment Management LLC

Confluence Investment Management LLC lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 85,793 shares of the medical research company’s stock after selling 6,988 shares during the quarter. Confluence Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $57,915,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $15,501,867,000. Corient Private Wealth LP acquired a new position in Thermo Fisher Scientific in the 2nd quarter worth about $382,547,000. Bank of New York Mellon Corp purchased a new position in Thermo Fisher Scientific during the second quarter worth approximately $1,974,561,000. Bank of America Corp DE acquired a new stake in Thermo Fisher Scientific in the second quarter valued at approximately $1,952,930,000. Finally, Auto Owners Insurance Co raised its stake in shares of Thermo Fisher Scientific by 57,845.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company’s stock worth $1,406,844,000 after buying an additional 2,423,706 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on TMO. Stifel Nicolaus set a $650.00 price target on shares of Thermo Fisher Scientific in a research note on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $720.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, September 25th. Jefferies Financial Group reissued a “buy” rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, September 12th. Finally, Evercore set a $570.00 price objective on Thermo Fisher Scientific in a research note on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average price target of $628.78.

Insider Buying and Selling

In other Thermo Fisher Scientific news, VP Lisa Britt sold 11,440 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the sale, the vice president directly owned 14,784 shares of the company’s stock, valued at $9,064,366.08. This trade represents a 43.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael Shafer sold 25,500 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 73,768 shares of company stock valued at $44,122,820 in the last quarter. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

TMO traded down $13.67 on Thursday, reaching $661.38. 1,001,570 shares of the company’s stock were exchanged, compared to its average volume of 2,247,437. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $683.63. The stock has a market cap of $244.54 billion, a PE ratio of 35.53, a P/E/G ratio of 2.84 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The stock’s fifty day moving average price is $615.28 and its 200-day moving average price is $532.54.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business’s revenue was up 10.5% on a year-over-year basis. During the same period last year, the company posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.